Insulin-Like Growth Factor Receptor Signaling in Thyroid Cancers: Clinical Implications and Therapeutic Potential

Chakravarty, Geetika; Mondal, Debasis

doi:10.5772/26732

Cited by 1 publication

(2 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NVP-AEW541 inhibited tumor growth more potently than irinotecan. Furthermore, NVP-AEW541 also reduced tumor angiogenesis, suggesting that IGF-IR modulates thyroid tumor microenvironment [86].…”

Section: Targeting Igf Signaling In Thyroid Cancermentioning

confidence: 99%

“…Aberrant activation of intracellular signaling involving the MEK pathway contributes to thyroid tumorigenesis since MEK inhibition favors differentiation of radioiodine-refractory DTCs by restoring NIS expression [86,95,96]. Hence, a number of specific MEKi have been evaluated in preclinical and clinical studies including several samples/patients diagnosed with thyroid cancer [97,98,99].…”

Section: Targeting Igf Signaling In Thyroid Cancermentioning

confidence: 99%

See 1 more Smart Citation

Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment

Manzella

Massimino

Stella

et al. 2019

IJMS

View full text Add to dashboard Cite

The Insulin-like growth factor (IGF) axis is one of the best-established drivers of thyroid transformation, as thyroid cancer cells overexpress both IGF ligands and their receptors. Thyroid neoplasms encompass distinct clinical and biological entities as differentiated thyroid carcinomas (DTC)—comprising papillary (PTC) and follicular (FTC) tumors—respond to radioiodine therapy, while undifferentiated tumors—including poorly-differentiated (PDTC) or anaplastic thyroid carcinomas (ATCs)—are refractory to radioactive iodine and exhibit limited responses to chemotherapy. Thus, safe and effective treatments for the latter aggressive thyroid tumors are urgently needed. Despite a strong preclinical rationale for targeting the IGF axis in thyroid cancer, the results of the available clinical studies have been disappointing, possibly because of the crosstalk between IGF signaling and other pathways that may result in resistance to targeted agents aimed against individual components of these complex signaling networks. Based on these observations, the combinations between IGF-signaling inhibitors and other anti-tumor drugs, such as DNA damaging agents or kinase inhibitors, may represent a promising therapeutic strategy for undifferentiated thyroid carcinomas. In this review, we discuss the role of the IGF axis in thyroid tumorigenesis and also provide an update on the current knowledge of IGF-targeted combination therapies for thyroid cancer.

show abstract

Section: Targeting Igf Signaling In Thyroid Cancermentioning

confidence: 99%